Oncolytics Biotech®, Inc. (OTC: ONCY) is a Calgary-based biotechnology company that focuses on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. So far, REOLYSIN® has shown promising activity in a variety of cancers. Oncolytics has received over 300 patents worldwide, including the U.S. and Canada, with more than 200 pending applications. For more information, visit the company’s website at www.oncolyticsbiotech.com